These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9622056)

  • 1. Antigen processing/presenting and oncogenesis.
    Abdelnoor AM
    Crit Rev Oncog; 1997; 8(4):381-93. PubMed ID: 9622056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor antigens and tumor vaccines: peptides as immunogens.
    Slingluff CL
    Semin Surg Oncol; 1996; 12(6):446-53. PubMed ID: 8914209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts.
    Sundstrom JB; Ansari AA
    Transpl Immunol; 1995 Dec; 3(4):273-89. PubMed ID: 8665146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dendritic cells and immune function in cancer].
    Chaux P
    Pathol Biol (Paris); 1995 Dec; 43(10):897-903. PubMed ID: 8786896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines in the treatment of cancer.
    Baltz JK
    Am J Health Syst Pharm; 1995 Nov; 52(22):2574-85; quiz 2594-5. PubMed ID: 8590245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene-based strategies for the immunotherapy of cancer.
    Tüting T; Storkus WJ; Lotze MT
    J Mol Med (Berl); 1997 Jul; 75(7):478-91. PubMed ID: 9253711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
    Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
    Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune control of tumors by antigen presentation improvement.
    Remedi MM; Bonacci G; Vides MA; Donadio AC
    Tumour Biol; 2003; 24(5):228-35. PubMed ID: 15001835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-specific antigens revisited: presentation to the immune system of fusion peptides resulting solely from tumor-specific chromosomal translocations.
    Pawelec G; Kalbacher H; Bruserud O
    Oncol Res; 1992; 4(8-9):315-20. PubMed ID: 1486216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies for enhancing the immunogenicity of tumors.
    Pardoll DM
    Curr Opin Immunol; 1993 Oct; 5(5):719-25. PubMed ID: 7694593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity.
    Foell J; Hewes B; Mittler RS
    Curr Cancer Drug Targets; 2007 Feb; 7(1):55-70. PubMed ID: 17305478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-1 expression by a non-antigen presenting cell-derived tumor.
    Antonia SJ; Muñoz-Antonia T; Soldevila G; Miller J; Flavell RA
    Cancer Res; 1995 Jun; 55(11):2253-6. PubMed ID: 7538898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
    Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
    Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The immune response to kidney allograft. Part I: the role of MHC antigens, antigen-presenting cells, and lymphocytes in alloantigen recognition; two-signal activation of T cells].
    Kusztal M; Jezior D; Weyde W; Krajewska M; Klinger M
    Postepy Hig Med Dosw (Online); 2007; 61():13-20. PubMed ID: 17245313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen-presenting human T cells and antigen-presenting B cells induce a similar cytokine profile in specific T cell clones.
    Wyss-Coray T; Gallati H; Pracht I; Limat A; Mauri D; Frutig K; Pichler WJ
    Eur J Immunol; 1993 Dec; 23(12):3350-7. PubMed ID: 7504995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?
    Altomonte M; Fonsatti E; Visintin A; Maio M
    Oncogene; 2003 Sep; 22(42):6564-9. PubMed ID: 14528281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines.
    Fenton RG; Turcovski-Corrales SM; Taub DD
    J Immunother; 1998 Mar; 21(2):95-108. PubMed ID: 9551360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.